Beyond the Bugs: An Overview of Advanced and Targeted Modalities in Infectious Disease Treatments, Including Biologics, Monoclonal Antibodies, and Bacteriophage Therapy
Infectious Disease Treatments are rapidly evolving, driven by the existential threat of antimicrobial resistance, which necessitates the urgent development of therapeutic alternatives to conventional antibiotics for life-threatening bacterial, viral, and fungal pathogens. Novel approaches are moving beyond broad-spectrum killing, focusing instead on highly targeted agents like monoclonal antibodies (mAbs) that neutralize specific toxins or pathogens, and the re-emergence of bacteriophage therapy.
The strategic deployment of these advanced therapies is essential to preserve the efficacy of older drugs and combat multi-drug resistant organisms (MDROs), particularly in hospital-acquired infections and immunocompromised populations. The group can analyze the mechanisms, clinical trial data, and regulatory hurdles associated with bringing these innovative treatments to market to address the looming global crisis of antibiotic ineffectiveness.